1 tablet contains ranitidine hydrochloride based on ranitidine 150 mg
excipients: lactose, povidone, cellulose microcrystalline, magnesium stearate, silicon dioxide colloidal, croscarmellose sodium, hypromellose, Polysorbate 80, titanium dioxide (E 171), talc, polyethylene glycol, colouring agent sunset yellow FCF (E 110).The
Tablet, film coated.
Basic physical and chemical properties:tablets, film-coated from light orange to orange in color, with facet. On a fault under a magnifying glass the kernel surrounded by one continuous layer is visible.The
preparations for the treatment of peptic ulcer disease and gastroesophageal reflux disease. Antagonists of the N2-receptors of histamine. ATC code A02B A02.The
Ranitidine is an antiulcer remedy, the antagonist of N2-receptors of histamine.
the Mechanism of action is due to competitive inhibition of h2-histamine receptors of the membranes of parietal cells of the gastric mucosa.
Reduces basal and stimulated secretion of hydrochloric acid, reducing the amount of gastric juice caused by irritation of baroreceptors (stretching of the stomach), nutritional stress, the action of hormones and biogenic stimulants (gastrin, histamine, pentagastrin, caffeine). Ranitidine reduces the amount of hydrochloric acid in gastric juice, does not affect the concentration of gastrin in blood plasma, as well as mucus production. Ranitidine is characterized by a long action.
Ranitidine does not affect the enzymatic system of cytochrome P450 in the liver.
Pharmacokinetics.after oral administration, ranitidine is rapidly absorbed in the gastrointestinal tract. Bioavailability is about 50%. Cmaxin the blood is achieved after 2-3 hours and is 478 ng/ml. Partially metabolized in the liver to N-oxide (the main metabolite, 4% dose), S-oxide and demethylated.
T?(after intake) under normal KK - 2 to 3 hours, under reduced (20-30 ml/min) is 8-9 hours. It is excreted by the kidneys within 24 hours, in unchanged form, about 30% of the orally taken dose is excreted.
Penetrates through gistogematicalkie barriers, including placental, but not through the blood-brain barrier. Quite significant concentrations are found in breast milk. The rate and extent of elimination little dependent on the state of the liver and are mainly related to kidney function.
hypersensitivity to ranitidine and other components of the drug presence of malignant diseases of the stomach, liver cirrhosis with portosystemic encephalopathy in history, severe renal failure (creatinine clearanceThe
Ranitidine may affect the absorption, metabolism and renal excretion of other drugs.
Ranitidine in therapeutic doses does not alter the activity of the enzyme system cytochrome P450 and potentiates the effect of drugs that are metabolized by this system (diazepam, lidocaine, phenytoin, propranolol, theophylline).
Ranitidine, changing the acidity of the stomach, may affect the bioavailability of certain drugs. This leads either to an increase in their absorption (triazolam, midazolam, glipizide), or to a decrease in their absorption (ketoconazole, Itraconazole, atazanavir, gefitinib).
Antacids and sucralfat slow down the absorption of ranitidine, resulting in an interval between taking these drugs and ranitidine should be at least 1-2 hours.
Concomitant use with metoprolol may result in increased serum concentrations of metoprolol.
Ranitidine at simultaneous application with anticoagulants cumarin (warfarin) can alter the prothrombin time (recommended monitoring PV).
High doses of ranitidine can slow down the excretion of procainamide and N-acetylprocainamide, which leads to the increase of their level in blood plasma.
no data are available on the interaction between ranitidine and amoxicillin or metronidazole.
Smoking reduces the efficacy of ranitidine.
in the presence of allergies to other drugs of the h blocker group2histamine receptors allergic reactions to ranitidine are possible, so in the presence of hypersensitivity to other drugs of this group, the drug should be used with caution.
be wary of drugs in acute porphyria (including in history), immunodeficiency.
Ranitidine is excreted by the kidneys, so in patients with severe renal insufficiency, its blood plasma levels are elevated (see Dosage for such patients in the section "administration And dosage").
in elderly patients with impaired liver or kidney function may be impaired (confusion) consciousness, which leads to the need to reduce the dose.
drug Treatment may mask symptoms of gastric carcinoma, therefore, before treatment should rule out a malignant neoplasms in the stomach.
the need for regular surveillance of patients (particularly the elderly and with the instructions history of peptic ulcer and/or duodenal ulcer) who take ranitidine along with NSAIDs.
elderly patients, persons with chronic lung disease, diabetes mellitus or persons with impaired immunity showed an increased tendency to develop community-acquired pneumonia.
drug Treatment must be withdrawn gradually because of the risk of development of a syndrome of "rebound" in the abrupt cancellation.
the Drug contains lactose, which should be considered in patients with rare hereditary forms of galactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.
use during pregnancy and or lactation.
the Drug is contraindicated in pregnancy. If necessary, the use of the drug should discontinue breast-feeding.The
Given that in sensitive patients when applying the drug may experience adverse reactions (dizziness, hallucinations, violation of accommodation), during the administration of the drug should refrain from driving vehicles or other mechanisms.
for adults and children over 14 years of age. Taken inside, not liquid, squeezed small amounts of water, regardless of meal.
gastric Ulcer and duodenal ulcer not associated with Helicobacter pylori (in acute phase).Prescribe 150 mg (1 tablet) twice a day morning and evening or 300 mg (2 tablets) once a day at night for 4 weeks. With ulcers, not scarred, continue treatment for the next 4 weeks.
Prevention of gastric ulcer and duodenal ulcers associated with NSAIDs.Appoint 150 mg (1 tablet) 2 times a day in the morning and evening for the period of therapy NSAIDs.
Functional dyspepsia.Prescribe 150 mg (1 tablet) twice a day in the morning and evening for 2-3 weeks.
Chronic gastritis with increased acid-producing function of the stomach in the acute stage.Prescribe 150 mg (1 tablet) twice a day in the morning and evening for 2-4 weeks.
Gastroesophageal reflux disease.For the relief of symptoms to assign a 150 mg (1 tablet) 2 times a day morning and evening for 2 weeks if necessary, the course of treatment to continue.
for long-term treatment and in case of exacerbation of gastroesophageal reflux disease appoint 150 mg (1 tablet) 2 times a day in the morning and evening or 300 mg (2 tablets) 1 once a day for the night for 8 weeks, if necessary, continue treatment for up to 12 weeks.
patients with severe renal insufficiency(creatinine clearanceThe
Children aged 14 years of use of the drug is shown to reduce the duration of treatment of gastric ulcer and duodenal ulcer, for the treatment and relief of symptoms of gastroesophageal reflux disease.
adverse reactions may increase.
Treatment:provide adequate symptomatic and supportive therapy if necessary. Ranitidine can be removed from the serum by hemodialysis.
by blood:leukopenia, reversible thrombocytopenia, agranulocytosis or pancytopenia, sometimes with hypoplasia or bone marrow aplasia, neutropenia, immune hemolytic and aplastic anemia (usually reversible).
from the immune system:hypersensitivity reactions, Including Urticaria, angioedema, fever, anaphylactic shock, bronchospasm, multiform exudative erythema, exfoliative dermatitis, Stevens-Johnson syndrome, Lyell's syndrome, hyperthermia.
on the part of the psyche:increased fatigue, reversible confusion, drowsiness, excitement, insomnia, emotional lability, anxiety, anxiety, depression, nervousness, hallucinations, tinnitus, irritability, disorientation, state of confusion. These manifestations are observed mainly in seriously ill or elderly patients.
nervous system:headache, dizziness and reverse involuntary motor disorders.
on the part of the visual organ:blurred visual perception, violation of accommodation.
on the part of the cardiovascular system:a reduction in blood pressure, bradycardia, tachycardia, asystole, AV blockade, vasculitis, chest pain, arrhythmia, extrasystoles.
from the digestive tract:dry mouth, nausea, vomiting, constipation, diarrhea, abdominal pain, flatulence, acute pancreatitis, decreased appetite.
from the digestive system:transient and reversible changes in liver function hepatocellular, cholestatic or mixed hepatitis with or without jaundice (usually revolving).
from the skin and subcutaneous tissue:hyperemia, itching, skin rashes, erythema multiforme, alopecia, dry skin.
From the side of musculoskeletal system:arthralgia, myalgia.
from the urinary system:impaired renal function, acute interstitial nephritis.
from the reproductive system:hyperprolactinemia, galactorrhea, gynecomastia, amenorrhea, reduced potency (reversible) and/or libido.The
Store in its original packaging at a temperature not exceeding 25 ° C. keep out of reach of children.The
10 tablets each in a blister. 1, 2 or 3 blisters in a pack of cardboard.The
According to the recipe.The
20300, Ukraine, Cherkassy region, . Uman, manuilskogo str., 8.
the Medicine Ranitidine belongs to the group of anti-ulcer drugs, whose action is based on the suppression of gastric juice production. This process forms suitable conditions for healing ulcers and erosions in the intestine and stomach, improves microcirculation in the digestive tract. Admission ranitidine appoint in cases of acute ulcerative disease of the gastrointestinal tract, as well as manifestations of various pathologies accompanied by hypersecretion.
the course of treatment with Ranitidine can last from 2 weeks to a month, depending on the reasons for its appointment. A single dose of the drug varies from 75 to 300 mg and is selected by the attending physician individually.